Compare VISTA PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VISTA PHARMA vs SHREE GANESH REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VISTA PHARMA SHREE GANESH REMEDIES VISTA PHARMA/
SHREE GANESH REMEDIES
 
P/E (TTM) x -11.7 33.0 - View Chart
P/BV x 1.1 7.4 14.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 VISTA PHARMA   SHREE GANESH REMEDIES
EQUITY SHARE DATA
    VISTA PHARMA
Mar-21
SHREE GANESH REMEDIES
Mar-21
VISTA PHARMA/
SHREE GANESH REMEDIES
5-Yr Chart
Click to enlarge
High Rs16345 4.7%   
Low Rs565 7.4%   
Sales per share (Unadj.) Rs0.349.0 0.7%  
Earnings per share (Unadj.) Rs-0.59.7 -5.3%  
Cash flow per share (Unadj.) Rs-0.312.5 -2.5%  
Dividends per share (Unadj.) Rs01.75 0.0%  
Avg Dividend yield %00.9 0.0%  
Book value per share (Unadj.) Rs8.950.0 17.9%  
Shares outstanding (eoy) m36.7910.01 367.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x30.34.2 726.1%   
Avg P/E ratio x-20.421.0 -97.0%  
P/CF ratio (eoy) x-33.216.4 -202.1%  
Price / Book Value ratio x1.24.1 28.5%  
Dividend payout %018.0 0.0%   
Avg Mkt Cap Rs m3842,051 18.7%   
No. of employees `000NANA-   
Total wages/salary Rs m1224 47.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m13491 2.6%  
Other income Rs m321 15.2%   
Total revenues Rs m16512 3.1%   
Gross profit Rs m-17136 -12.7%  
Depreciation Rs m727 26.7%   
Interest Rs m151 2,277.9%   
Profit before tax Rs m-37129 -28.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1832 -56.4%   
Profit after tax Rs m-1998 -19.3%  
Gross profit margin %-136.627.8 -491.2%  
Effective tax rate %48.924.7 198.1%   
Net profit margin %-148.919.9 -749.1%  
BALANCE SHEET DATA
Current assets Rs m152380 40.1%   
Current liabilities Rs m92102 90.8%   
Net working cap to sales %473.256.7 835.1%  
Current ratio x1.63.7 44.2%  
Inventory Days Days2,40936 6,704.1%  
Debtors Days Days6,25499,126,372 0.0%  
Net fixed assets Rs m374226 165.3%   
Share capital Rs m74100 73.5%   
"Free" reserves Rs m255400 63.7%   
Net worth Rs m328500 65.7%   
Long term debt Rs m870-   
Total assets Rs m526606 86.8%  
Interest coverage x-1.4191.4 -0.7%   
Debt to equity ratio x0.30-  
Sales to assets ratio x00.8 3.0%   
Return on assets %-0.616.2 -3.9%  
Return on equity %-5.719.5 -29.4%  
Return on capital %-5.126.0 -19.8%  
Exports to sales %074.6 0.0%   
Imports to sales %023.1 0.0%   
Exports (fob) Rs mNA366 0.0%   
Imports (cif) Rs mNA113 0.0%   
Fx inflow Rs m1366 0.3%   
Fx outflow Rs m0113 0.0%   
Net fx Rs m1253 0.4%   
CASH FLOW
From Operations Rs m-6733 -203.8%  
From Investments Rs m-3-9 31.7%  
From Financial Activity Rs m70-7 -1,059.5%  
Net Cashflow Rs m-117 -5.0%  

Share Holding

Indian Promoters % 2.0 69.1 3.0%  
Foreign collaborators % 34.9 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.1 30.9 204.2%  
Shareholders   13,004 4,814 270.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VISTA PHARMA With:   ORCHID PHARMA  MEDICO REMEDIES   GLAND PHARMA  RPG LIFE SCIENCES  LYKA LABS  



Today's Market

Sensex Zooms 777 Points, Nifty Ends Above 17,400; Power & IT Stocks Rally(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VISTA PHARMA SHARE PRICE


Dec 2, 2021 (Close)

TRACK VISTA PHARMA

  • Track your investment in VISTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

VISTA PHARMA 5-YR ANALYSIS

COMPARE VISTA PHARMA WITH

MARKET STATS